Increasing Accuracy of Current Diagnostics in MS
It is difficult to determine whether a patient suffering from a first demyelinating event will or will not go on to develop relapsing Multiple Sclerosis. The current way of determining risk of conversion to relapsing MS after a first demyelinating event is to measure MRI parameters and determine whether or not the patient has unique spinal fluid antibodies called oligoclonal bands using a test that was developed over fifty years ago. These tests are helpful, but fall short in their ability to provide accurate and detailed prognostic information for patients and their physicians. Dr. Schubert and his team are leveraging advancements in genomics, computer science, and clinical medicine to test whether a comprehensive picture of a patient’s spinal fluid antibody “fingerprint” can improve the predictive power and accuracy of current MS diagnostics.
The American Brain Foundation is proud to partner with the National Multiple Sclerosis Society to support this project.